A drug application that lets the FDA begin reviewing completed portions before the full package arrives has reached federal regulators for a treatment targeting a serious, rare condition with no approved therapies in the United States. Palvella Therapeutics (Nasdaq: PVLA) submitted the first module of that rolling New Drug Application, a phased filing process the FDA grants to allow parallel review of completed sections, for QTORIN rapamycin in microcystic lymphatic malformations. The Wayne, Pennsylvania company reported $250.6 million in cash, cash equivalents, and short-term investments as of June 30, 2026.
NDA submission and the path to a 2027 launch
Palvella completed an in-person pre-NDA meeting with the FDA before initiating the rolling submission, covering nonclinical, clinical pharmacology, clinical information, and the planned evidence package. The agency then granted Rolling Review status for the program, allowing simultaneous evaluation of completed sections rather than holding review until a full submission lands. QTORIN rapamycin carries both Breakthrough Therapy and Fast Track designations for this indication. Those two FDA pathways are designed to expedite development and review of therapies for serious conditions with unmet medical need.
Full NDA completion is on track for the second half of 2026. A standalone U.S. commercial launch is planned for the first half of 2027, if the FDA approves. Commercial and medical affairs leaders are already placed in the field executing pre-launch activities.
James Treat, M.D., of Children's Hospital of Philadelphia presented additional Phase 3 SELVA data at the International Society for the Study of Vascular Anomalies World Congress, including statistically significant improvement in the six-to-eleven-year-old patient cohort and improvements in clinical signs and patient-reported outcomes.
Pipeline progress across four programs
Three other QTORIN programs moved forward during the quarter. In the Phase 2 TOIVA trial for cutaneous venous malformations, 100 percent of patients who had bleeding at baseline showed improvement on the Cutaneous Venous Malformations Investigator Global Assessment Bleeding scale at Week 12. Phase 3 trial initiation for that indication is on track for the fourth quarter of 2026.
The first patients were dosed in LOTU, a multicenter Phase 2 trial testing QTORIN rapamycin for clinically significant angiokeratomas. That condition has no FDA-approved therapy and affects an estimated more than 50,000 diagnosed patients in the United States. Topline results from LOTU are expected in the second half of 2027.
Palvella's second product candidate, QTORIN pitavastatin, targets disseminated superficial actinic porokeratosis, a premalignant genetic skin disease estimated to affect more than 50,000 diagnosed patients in the U.S. with no FDA-approved treatment. U.S. Patent No. 12,636,273 was issued and exclusively licensed from Yale University, building on research by Keith Choate, M.D., Ph.D. It covers topical administration of HMG-CoA reductase inhibitors for treatment of porokeratosis and runs through 2043. Phase 2 trial initiation is expected in the second half of 2026.
Cash position and corporate moves
Cash, cash equivalents, and short-term investments totaled $250.6 million as of June 30, 2026. Palvella completed an uplisting to the Nasdaq Global Market and named Matt Pauls, J.D., M.B.A., to its Board of Directors. Pauls previously held executive and board roles at Savara Inc., Soleno Therapeutics, Strongbridge Biopharma, and Insmed Incorporated. The company plans to announce a fourth target clinical indication for QTORIN rapamycin and a third product candidate from the QTORIN platform, both in the second half of 2026.